Xing-liang Li

High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion

L. Mao, Wenliang Zhu, Z. Song, 2021, Cancer communications.

Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors.

M. Fang, You‐cai Zhu, Wenxian Wang, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib

You‐cai Zhu, Wenxian Wang, Chun-wei Xu, 2019, BMC Cancer.

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib

J. Ji, Wenxian Wang, J. Tu, 2019, OncoTargets and therapy.

OTT_A_218796 9303..9307

J. Ji, Wenxian Wang, J. Tu, 2019 .

Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing.

Gang Chen, T. Lv, Yong Song, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer

Y. Shao, Yiping Zhang, Z. Song, 2020, Translational oncology.

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib

Li-xin Wu, B. Wan, You‐cai Zhu, 2019, Translational cancer research.

Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients

Wei-tian Wei, Xing-liang Li, Changchun Wang, 2020, OncoTargets and therapy.